Introduction: Patients with end-stage renal disease (ESRD) have reduced endothelial function, but whether macro-and microvascular endothelial function correlate with baseline risk factors and cardiovascular outcomes in this population is not well understood.
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INTRODUCTION
Patients with end-stage renal disease (ESRD) who initiate dialysis have a ten to twentyfold higher risk of cardiovascular mortality than individuals without kidney disease, even after adjustment for risk factors such as age and diabetes. 1 Of the over 400,000 Americans on hemodialysis, 2 70% have overt atherosclerotic disease and 45% suffer from heart failure. 3 Cardiovascular morbidity and mortality remain high among this population, even after optimal treatment for volume overload, 4 ,5 hypertension, 6 hyperkalemia, 7 and hyperparathyroidism. 8 Endothelial dysfunction is common among patients with chronic kidney disease (CKD) and correlates with severity of renal failure. 9 Although patients with ESRD have severely reduced endothelial function, 9 ,10 studies in the ESRD population are inconsistent as to whether endothelial dysfunction predicts clinical outcomes. 11, 12 Furthermore, statin therapies, known to be effective in lower risk populations for primary and secondary cardiovascular disease prevention [13] [14] [15] through lowering lipid levels and improving endothelial function, 16 were not effective compared to placebo in two large ESRD trials. 17, 18 Thus, whether endothelial dysfunction is a meaningful or modifiable risk factor in this population is not well understood. Forearm reactive hyperemia is a gold-standard measure of endothelial function 19 and correlates well with invasively measured coronary endothelial dysfunction. 20 Parameters derived from forearm reactive hyperemia include flow-mediated dilation (FMD) of the brachial artery, a measure of macrovascular endothelial dysfunction, and velocity time integral (VTI), a measure of microvascular endothelial dysfunction. 21 To our knowledge, FMD and VTI have not been performed simultaneously in a prior ESRD cohort, nor have their associations with cardiovascular outcomes in this population been compared.
The Cardiac, Endothelial Function and Arterial Stiffness in ESRD (CERES) cohort is a prospective observational study designed to investigate vascular dysfunction, myocardial injury and cardiovascular outcomes in ESRD. In these analyses, we aimed to investigate associations of endothelial function with baseline cardiovascular risk factors and to determine associations of macrovascular (FMD) and microvascular (VTI) endothelial dysfunction with the composite outcome of cardiovascular hospitalization or mortality.
MATERIALS AND METHODS

Study population
CERES participants were recruited in person and by mail from the University of California, San Francisco (UCSF) Kidney Pancreas Transplant Clinic, the Zuckerberg San Francisco General (ZSFG) Hospital Chronic Dialysis Unit, and five Fresenius and DaVita dialysis units between February 2013 and April 2016. To be included, patients had to be on hemo-or peritoneal dialysis for at least one month. Any one of the following led to exclusion: myocardial infarction in the prior four months, current infection, newly diagnosed or metastatic cancer or currently on chemotherapy, cocaine or intravenous drug use in the last six months, or major surgery within the last month. For these analyses we included all participants with vascular measures and at least six months of clinical follow-up. Patients gave written informed consent and the UCSF Committee for Human Research approved the study protocol. All procedures were in accordance with the Declaration of Helsinki. 22 
Baseline covariates
Demographics and comorbidities were collected by selfreport and confirmed by medical chart review whenever possible. History of atherosclerotic disease included history of myocardial infarction, stroke, percutaneous coronary intervention, coronary artery bypass surgery, or peripheral artery disease. The Charlson Comorbidity Score 23 was calculated using an online calculator. 24 Height, weight, and blood pressure were measured on the day of the study visit. Blood pressure was measured by a trained technician (CM) with a sphygmomanometer on the arm free of prior vascular surgery. Participants rested supine for 10 minutes in a quiet, temperature-controlled room, before peripheral systolic blood pressure (SBP) was measured by automated sphygmomanometer using an appropriately sized cuff placed on the proximal antecubital fossa. Blood pressure was measured at two time points, 5 minutes apart. If the two blood pressure measurements differed by more than 10 mmHg, the measurement was repeated every 5 minutes until repeat SBP's were within 10 mmHg, after which the final blood pressure was noted as the blood pressure obtained prior to FMD. Dry weight was drawn from each patient's hemodialysis orders current with the study visit, obtained from the dialysis unit. To estimate the degree of volume overload for each patient, the variable 'weight over dry weight' was calculated by subtracting (dry weight) from (weight after last dialysis session). We opted not to use the patient's weight on the day of the study visit in order to avoid differences between scales at the study site and the dialysis units.
Biomarker measurements
Calcium, phosphorus, albumin, parathyroid hormone, inflammatory, and cardiac markers were drawn the day of the study visit and processed at the University of Maryland laboratory. High sensitivity cardiac Troponin T (hs-TnT) and N-terminal pro B-type natriuretic peptide (NT-proBNP) measurements were performed on the e 601 cobas analyzer (Roche Diagnostics, Indianapolis, Indiana). The analytical measurement range for the hs cTnT assay is 3 to 10,000 ng/l with a 99th percentile of a healthy reference population defined at 14 ng/L and a 10% coefficient of variation less than the 99th percentile. 25 The coefficient of variation for the NT-proBNP assay was 2% to 5% during the testing period, with an analytical measurement range 5-35,000 ng/L. IL-6 was measured on the IMMULITE 2000 analyzer (Siemens Healthcare, Newark, DE). The analytical sensitivity of this assay is 2 ng/L; the upper limit of normals (97.5th percentile) is 3.4 ng/L, and the undiluted measurement range is up to 1000 ng/L. The precision of the assay is <6.0% (%CV) across the measurement range. Highsensitivity CRP (hs-CRP) measurements were performed on the Dimension Vista (Siemens Healthcare, Newark, DE). The hs-CRP values associated with cardiovascular risk are as follows: low risk < 1.0 mg/L; average risk 1.0-3.0 mg/L; high risk > 3.0 mg/L. 26 Precision of the assay was <5.2% across the measurement range.
Endothelial measures
Study visits occurred at the ZSFG Clinical Research Center on either Tuesday or Wednesday morning (for hemodialysis patients, the morning following the first dialysis session of the week). Patients were instructed to take their regular medications and to avoid heavy meals, caffeine and smoking 12 hours prior to the study visit (compliance with instructions was 84%, 89%, 90%, and 100%, respectively). FMD was performed by ultrasound in patients with an arm free of vascular access (functional or not) or other surgical intervention. The ultrasound technician recorded baseline 2D and Doppler images of the brachial artery, then the cuff was inflated for 5 minutes. Doppler flow was recorded immediately following cuff release. Occlusion pressure was at least 50 mmHg above peripheral SBP, and no more than 300 mmHg. Brachial diameter was measured at 60 seconds and 90 seconds following cuff deflation. Anticipating that FMD values would be very low in an ESRD cohort, we placed the cuff on the upper arm, an accepted site of cuff occlusion that typically results in FMD values twice as large as distal placement. 19 A single ultrasound technician (CM) performed all FMD study procedures and confirmed using 2D imaging and Doppler whether the artery was fully compressible at 50 mmHg above SBP, up to a maximum inflation pressure of 300 mmHg. For most participants, the occlusion cuff pressure was between 240 mmHg and 300 mmHg. We used a maximal cuff pressure of 300 mmHg for seven participants whose arteries were not fully compressible at 300 mmHg. FMD images were de-identified and transferred in DICOM format to the ZSFG Center for Excellence in Vascular Research for analysis. Brachial artery diameters before and after cuff deflation were measured manually from the intima-media interfaces using MIA software (Medical Imaging Applications, Coralville, Iowa). The 60-second FMD image was used for analysis in all participants except for two, whose 90-second image was significantly clearer than at 60 seconds. Image quality was generally excellent; only 6 of 106 values could not be measured due to suboptimal imaging. Brachial diameter during hyperemia was measured at five consecutive, regular R-R intervals. 27 In the presence of arrhythmia (nine patients), if at least three consecutive regular R-R intervals for FMD and at least two for VTI could not be ascertained, these images were dropped from the analysis (two for FMD, three for VTI). (Supporting Information Figure 1 ) The FMD (percent change) was calculated at the 60-second time-point as ([post-inflation diameter) − (pre-inflation diameter])/(preinflation diameter) × 100%. VTI was measured by manually tracing the pulse wave in the MIA software, then calculated using MIA algorithms. Baseline VTI was measured prior to cuff inflation, and hyperemic VTI was measured as the average VTI of the first three full cardiac cycles following cuff deflation. 27, 28 Delta VTI was calculated as (hyperemic VTI) − (baseline VTI) and ratio VTI as (delta VTI)/ (baseline VTI).
Reproducibility of endothelial measures
Eleven patients returned on the day after dialysis for repeat quality control studies performed 7 days following the initial visit. Mean (±SD) absolute difference in FMD and VTI between study visits were 1.6% (±1.4) and VTI (CM) were asked to evaluate de-identified duplicate studies in random order. For these duplicates, intraobserver CV for FMD was 0.17% and intra-observer CV for VTI was 0.03%.
Outcome adjudication
Participants were followed up to 2 years or until the date of death or transplant, which was ascertained by contacting the patient, dialysis unit, or family. We called patients every 6 months to inquire if they had been hospitalized since the study visit. Reason for hospitalization was initially determined by patient interview or by search of the electronic record for patients seen within the ZSFG and UCSF systems (47% were in the ZSFG system and 25% in the UCSF system). Hospitalizations were adjudicated by the principal investigator (who was blinded to the subject's vascular measures) as cardiovascular if one of the following was a primary diagnosis: myocardial infarction, heart failure, pulmonary embolism, percutaneous coronary intervention, coronary artery bypass surgery, or valvular surgery. Hospital admissions for volume overload or electrolyte abnormality attributed primarily to missed dialysis session(s) were not considered cardiovascular. Participants who were transplanted (n = 17) or lost to follow-up (n = 15) were censored.
Statistical analyses
First, we examined demographics and comorbidities among participants grouped by quartile of VTI or FMD. We also tested Spearman correlations between vascular, inflammatory, and volume status markers and the linear variables, VTI and FMD. Crude 1-year event-free survival was calculated for each quartile of VTI and FMD. Cox survival analysis was performed for each vascular parameter in units of one standard deviation of the parameter, to facilitate comparison of effect sizes. Survival analyses were adjusted for covariates that differed among participants in different quartiles of hyperemic VTI (age, gender, race, dialysis modality, atherosclerosis, beta blocker use, angiotension converting enzyme or angiotensin receptor blocker (ACE/ARB) use), or ratio VTI (body mass index (BMI), diabetes, vascular access). We included SBP and heart rate in the model because of their associations with adverse outcomes in ESRD patients. 29, 30 Likewise, we adjusted for biomarkers of inflammation 31 (albumin, IL-6, hs-CRP) and cardiovascular risk (hs-TnT and NT-proBNP 
RESULTS
Demographic and baseline clinical characteristics for CERES participants by quartile of hyperemic VTI are displayed in Table 1 . Similar tables of baseline characteristics for patients grouped by ratio VTI and FMD are found in Supporting Information. The mean (±SD) age among participants was 56 (±13) years and 81% of patients were on hemodialysis, with a median(IQR) time on dialysis of 37 (18, 71) months. The lowest number of months on dialysis was 2 months. 30% of participants were women and 44% had diabetes. The mean (±SD) and range for each parameter of microvascular function were as follows: baseline VTI 15 cm (±11), range 5.1-51cm; hyperemic VTI 66 cm (±29), range 7.1-140 cm; delta VTI 51 cm (±28), range −22 to 113 cm; ratio VTI 4.1 cm (±2.5), range −0.36 to 12.
Participants with the lowest values of hyperemic VTI, representing those with worse microvascular function, were more likely to be older, Black, and have a higher Charlson Comorbidity Score (P < 0.05); although differences did not reach statistical significance, these participants tended to be female, to be on hemodialysis, have atherosclerosis, and to take beta-blockers or ACE/ARB (P < 0.2) ( Table 1) . Participants with the most impaired values of ratio VTI had higher Charlson Comorbidity Scores (P < 0.005), were more likely to be older, female, to be on hemodialysis, have diabetes or atherosclerosis, vascular access, have higher BMI, and to take statins (P < 0.2) (Supporting Information Table 1 ). NT-proBNP was substantially elevated and high-sensitivity Troponin T (hs-TnT) was well above the 99th percentile (i.e., 14 ng/L) of healthy individuals for all VTI quartiles. Higher levels of c-reactive protein, interleukin-6, hs-TnT and NT-proBNP correlated with worse microvascular function when the latter was analyzed as a continuous variable, although these correlations did not reach statistical significance after accounting for multiple comparisons (Table 2) .
Among 146 patients with VTI measures, mean (±SD) follow-up time was 437 (227) days and there were a total of 34 events (11 deaths, 23 cardiovascular hospitalizations). Due to three of these patients having inadequate baseline images, 143 had delta VTI or ratio VTI measures; among these, mean follow-up time was 435 days and there were 32 events. Whether calculated as hyperemic VTI, delta VTI, or ratio VTI, there was a graded, inverse association of higher ratio VTI (representing better The Kaplan-Meier curves (logrank P < 0.001) for quartiles of delta VTI are shown in Figure 1 . Conversely, higher SBP was associated with a higher rate of hospitalizations and deaths ( Figure 2 ). Both delta VTI and ratio VTI remained significantly associated with the composite outcome after adjustment for age. Ratio VTI was the only microvascular parameter that remained significantly associated with the outcome after adjustment for comorbidities or markers of inflammation and cardiac injury (Table 3) . Baseline characteristics by quartile of FMD are displayed in Supporting Information Table 2 . Range and mean (±SD) for macrovascular parameters were as follows: baseline brachial artery diameter mean (±SD) 4.7 mm (0.73), range 3.1 to 6.6 mm; delta diameter mean (±SD) 0.23 mm (0.14), range 0.004-0.55 mm; FMD mean (±SD) 5.1% (3.3), range 0%-14.7%. When grouped by quartile of FMD, participants with the lowest (worst) FMD were more likely to be Black, diabetic, and to have higher SBP (Supporting Information Table 2 ). When analyzed as a continuous variable, lower FMD was significantly correlated with larger brachial artery diameter, higher SBP, volume overload, and higher hs-TnT (Table 2) Categorical data are shown as N(%). Continuous data are summarized as mean(±SD) or median(IQR); P values calculated using chi 2 or ANOVA. a Atherosclerosis defined as self-report of at least one of the following: myocardial infarction, stroke, percutaneous cardiac intervention, coronary artery bypass graft, or peripheral artery disease. b SBP (mmHg): systolic blood pressure, measured in millimeters of mercury. c DBP (mmHg): diastolic blood pressure, measured in millimeters of mercury. d Kilograms over dry weight: the study participant's dialysis session the day before the study visit was reviewed, and kilograms over dry weight was calculated as post-dialysis weight -dry weight. This parameter represents the degree of volume overload and was not measured in peritoneal patients. e NT-proBNP: N-terminal pro B-type natriuretic peptide. 
DISCUSSION
In the CERES cohort, microvascular function, quantified as VTI during brachial artery hyperemia, was associated with higher rates of cardiovascular hospitalizations and overall mortality among ESRD patients on dialysis. In contrast, we did not observe a significant association of macrovascular dysfunction (FMD) with the outcome. Significant correlates of VTI included older age, Black race, inflammation, and myocardial injury. Endothelial function refers to the process by which nitric oxide, produced by the vascular endothelium, promotes vasodilation and inhibits inflammation, leukocyte adhesion, platelet aggregation, and vascular smooth muscle proliferation. 33 2D ultrasound of brachial artery dilation and Doppler imaging of blood flow augmentation during hyperemia permit quantification of FMD (macrovascular function) and VTI (microvascular function), 21 respectively. Increased blood flow during hyperemia augments shear stress, a stimulus for activation of endothelial nitric oxide synthase, which in turn produces nitric oxide that acts on the vascular smooth muscle to cause vasodilation. 33 Thus, consistent with our findings, one would expect FMD and VTI to be highly correlated since VTI serves as the stimulus for FMD.
The correlations we observed of older age and inflammation with VTI are consistent with prior studies. Aging leads to endothelial dysfunction through several pathways including oxidative stress, reduction of nitric oxide bioavailability, release of cyclooxygenase (COX)-derived vasoconstrictive factors, and activation of pro-inflammatory cytokines. 34 As shown in Table 2 , there was a significant correlation between inflammatory biomarkers (C-reactive protein or IL-6) and hyperemic VTI. Multiple links between inflammation and endothelial function have been delineated. IL-6 is both a marker and causal mediator of atherosclerosis. 35 Anti-inflammatory effects of nitric oxide include inhibition of leukocyte adhesion 36 and platelet aggregation, 37 both of which precede atherosclerotic plaque formation.
Chronic myocardial injury, measured as hs-TnT, correlated with impaired VTI or FMD. Brachial artery hyperemia is considered a surrogate for coronary artery endothelial function. 20 CKD and ESRD are associated with low nitric oxide bioavailability, which could cause chronic myocardial 'demand' ischemia because the coronary arteries or microvasculature cannot adequately vasodilate in response to oxygen demand. NT-proBNP, a marker of hemodynamic stress and volume overload, is a strong predictor of adverse outcomes in patients with CKD 38 or ESRD. 32 We observed a stronger association of NT-proBNP with VTI than with FMD; there are several potential explanations for the NT-proBNP -VTI correlation. Worse myocardial microvascular function may cause myocardial ischemia, which would worsen ventricular stiffness and wall stress. Alternatively, upstream mediators such as inflammation and oxidative stress may cause both microvascular and myocardial inflammation in parallel, and the latter may lead to ventricular stiffening. It is notable that FMD correlated with higher SBP, larger brachial diameter, and volume overload. Similar associations of FMD with higher blood pressure 39 and larger brachial artery diameter 40, 41 have been observed in non-CKD cohorts.
In the CERES cohort, VTI had stronger associations than did FMD with baseline characteristics such as age, race, inflammation, atherosclerotic disease, and Charlson Comorbidity Score. This is in accordance with findings in non-CKD cohorts such as Framingham. 39, 42 Additionally, the association of VTI with the composite outcome was statistically significant and had a larger effect size compared to FMD. In the Firefighters and Their Endothelium (FATE) cohort, VTI was a stronger predictor of cardiovascular events than FMD. 43 The FATE investigators proposed that, if one assumes microvascular endothelial function precedes macrovascular disease, the greater prognostic utility of VTI in their cohort might be explained by the young age and low prevalence of cardiovascular disease in the FATE cohort. 43 However, this hypothesis would not explain our findings because the participants of the CERES cohort were neither young nor free of prevalent cardiovascular disease.
It is interesting to note that the endothelial measures had different associations with SBP and diastolic blood pressure (DBP). Higher SBP was correlated with lower FMD (representing worse macrovascular function), but not with VTI. Higher DBP tended to correlate with higher VTI (representing better microvascular function). It is possible that the DBP-VTI association is due to methodological artifact, in that higher DBP could cause higher blood flow velocity. The absence of significant association of SBP with VTI, and the fact that these two parameters have inverse associations with the outcome, support that SBP and VTI are distinct entities in this population.
We considered carefully whether our methods and results were comparable with VTI studies in other cohorts. As expected, our measurements of VTI were correlated with history of atherosclerosis and inflammation. The mean (±SD) FMD and VTI in our cohort were markedly lower than those measured in FATE, a cohort of healthy male firefighters with a mean (±SD) FMD of 8.6%(4.1) and VTI of 122 cm (40.2) . 43 Prior studies using FMD as a measure of endothelial function among CKD patients showed similarly reduced measures of endothelial function. 9, 12 There are minor differences in the measurement of VTI between the CERES and FATE cohorts. We calculated VTI as the average integral of the first three beats following cuff deflation, 27, 28 as opposed to recording the peak integral of the first full beat. 43 Since blood flow during each systole gradually diminishes following cuff release, our measurements may be biased toward slightly lower values, which could contribute to the difference in VTI between the two cohorts.
Our study has several strengths. We performed simultaneous measures of macrovascular and microvascular function, in a well-controlled, carefully phenotyped ESRD cohort. Study visits and measurements were deliberately All predictors were normally distributed in raw form. The hazard ratio is expressed as increased risk per SD of the predictor. Model 1: age, systolic blood pressure, heart rate. Model 2: Model 1 + Black race, gender, dialysis modality, diabetes, atherosclerotic disease, fistula or graft vascular access, beta-blocker, ACE, or ARB + BMI. Model 3: Model 1 + albumin, ln(crp), ln(il6), ln(hs-troponin T), ln(NT-proBNP).
timed in relation to dialysis session since hemodialysis is known to influence endothelial function. 44 The study was conducted prospectively to focus on cardiovascular endpoints among patients with ESRD, and we present over 1 year of follow-up. The study also has several potential limitations. Notably, the study participants were relatively young and healthy for ESRD patients. Participants are likely to represent medically compliant patients, judging by their euvolemic status and well-controlled blood pressure. Thus, our results may not be generalizable to sicker patients or patients who are treatment non-compliant. Erythropoietin stimulating agents (ESAs), commonly used to treat anemia in dialysis patients, can exacerbate hypertension 45, 46 via disruption of endothelial calcium channels 47 or alterations in serum levels of asymmetric dimethylarginine. 48 Over 90% of CERES participants were on ESA's, but dosage was not equivalent for each ESA formulation; therefore, we did not include ESA dose in our analyses. Finally, the modest sample size of CERES predisposes our analyses to type II error.
In summary, we show that microvascular function, quantified as VTI during brachial artery hyperemia, was associated with higher rates of cardiovascular hospitalizations and overall mortality among individuals with ESRD on dialysis. Our findings suggest that microvascular endothelial function is a potential therapeutic target in this high-risk population. 
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